Why the study?
To summarise evidence comparing the risk of myocarditis and/or pericarditis following mRNA COVID-19 vaccination versus the risk in unvaccinated individuals without COVID-19 infection.
Does at least one dose of an mRNA COVID-19 vaccine increase the risk of myocarditis and/or pericarditis in individuals without SARS-CoV-2 infection compared to unvaccinated individuals?
Does at least one dose of an mRNA COVID-19 vaccine increase the risk of myocarditis and/or pericarditis in individuals without SARS-CoV-2 infection compared to unvaccinated individuals?
mRNA COVID-19 vaccination is associated with a twofold increased risk of myocarditis or pericarditis within 30 days compared to unvaccinated individuals in the absence of COVID-19 infection.
Answers are grounded in this paper and cite their sources.
Prompts risk-benefit discussions before mRNA vaccination; confirms association in meta-analysis of observational data.
OBJECTIVE: To summarise the available evidence on the risk of myocarditis and/or pericarditis following mRNA COVID-19 vaccination, compared with the risk among unvaccinated individuals in the absence of COVID-19 infection. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic databases (Medline, Embase, Web of Science and WHO Global Literature on Coronavirus Disease), preprint repositories (medRxiv and bioRxiv), reference lists and grey literature were searched from 1 December 2020 until 31 October 2022. STUDY SELECTION: Epidemiological studies of individuals of any age who received at least one dose of an mRNA COVID-19 vaccine, reported a risk of myo/pericarditis and compared the risk of myo/pericarditis to individuals who did not receive any dose of an mRNA COVID-19 vaccine. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently conducted screening and data extraction. The rate of myo/pericarditis among vaccinated and unvaccinated groups was recorded, and the rate ratios were calculated. Additionally, the total number of individuals, case ascertainment criteria, percentage of males and history of SARS-CoV-2 infection were extracted for each study. Meta-analysis was done using a random-effects model. RESULTS: Seven studies met the inclusion criteria, of which six were included in the quantitative synthesis. Our meta-analysis indicates that within 30-day follow-up period, vaccinated individuals were twice as likely to develop myo/pericarditis in the absence of SARS-CoV-2 infection compared to unvaccinated individuals, with a rate ratio of 2.05 (95% CI 1.49-2.82). CONCLUSION: Although the absolute number of observed myo/pericarditis cases remains quite low, a higher risk was detected in those who received mRNA COVID-19 vaccinations compared with unvaccinated individuals in the absence of SARS-CoV-2 infection. Given the effectiveness of mRNA COVID-19 vaccines in preventing severe illnesses, hospitalisations and deaths, future research should focus on accurately determining the rates of myo/pericarditis linked to mRNA COVID-19 vaccines, understanding the biological mechanisms behind these rare cardiac events and identifying those most at risk.
No takes yet. Share an insight, caveat, or question.
Alami et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: